JP5384362B2 - 角膜疾患を処置するための点眼剤の形態の医薬の調製におけるl−カルニチンの使用 - Google Patents
角膜疾患を処置するための点眼剤の形態の医薬の調製におけるl−カルニチンの使用 Download PDFInfo
- Publication number
- JP5384362B2 JP5384362B2 JP2009540692A JP2009540692A JP5384362B2 JP 5384362 B2 JP5384362 B2 JP 5384362B2 JP 2009540692 A JP2009540692 A JP 2009540692A JP 2009540692 A JP2009540692 A JP 2009540692A JP 5384362 B2 JP5384362 B2 JP 5384362B2
- Authority
- JP
- Japan
- Prior art keywords
- acid
- carnitine
- medicament
- vitamin
- nutritional supplement
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/728—Hyaluronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
−上皮:主に外来物質、例えば粉塵または水の、眼および角膜の他の層への通過を阻止するよう機能し酸素および涙に含まれる他の必要な細胞の栄養分を吸収する滑らかな表面を提供する。この層は、約5細胞の深さであり、何千もの小さな神経終末で満たされており、これが擦ったり引掻いた際の痛みに対して角膜を非常に敏感にしている。
−5-15%の用量のL-カルニチン;好ましい用量は10%である;
−0.05-4%の用量のタウリン、好ましい用量は2%である;
−0.05-1.5%の用量のヒアルロン酸ナトリウム、好ましい用量は0.2%である;
−0.05-1.0%の用量のビタミンE、好ましい用量は0.2%である;
−0.01-0.1 mg/Lの用量のマンガン、好ましい用量は0.051 mg/Lである;
−0.5-1.5 mg/Lの用量の亜鉛、好ましい用量は1.02 mg/Lである;
−5-5000 mg/Lの用量のナトリウム、好ましい用量は30 mg/Lである;
−1-1000 mg/Lの用量のカリウム、好ましい用量は9 mg/Lである。
・電気的角膜厚測定
・共焦点顕微鏡法
・対比感度
角膜厚測定を用いて本発明の点眼剤の投与前および後に得られた値の分析から、中心および中心傍帯の両方において角膜の厚さが約25%減少することが分かり、これは投与後約4-6時間持続した。
点眼剤(約1200 mOsm/L)
L-カルニチン 10%
タウリン 2%
ヒアルロン酸ナトリウム(sodium jaluronate) 0.2%
ビタミンE 0.2%
亜鉛 1.02 mg/L
マンガン 0.051 mg/L
ナトリウム 30 mg/L
カリウム 9 mg/L
ナトリウムメルチオレート 0.02 mg/mL
脱塩水体積 5 mL/バイアル
Claims (5)
- 活性成分として、
L-カルニチン、または製薬的に許容されるその塩 5-15%;
タウリン 0.05-4%;
ヒアルロン酸ナトリウム 0.05-1.5%;
ビタミンE 0.05-1.0%;
亜鉛 0.5-1.5 mg/L;
マンガン 0.01-0.1 mg/L;
ナトリウム 5-5000 mg/L;
カリウム 1-1000 mg/L;および
必要に応じて1以上の眼科学的に許容される賦形剤および/または希釈剤を含む、眼科用途のための、点眼剤の形態の、角膜浮腫の処置または予防のための、生理学的栄養補助剤または医薬。 - 以下の組成を有する、請求項1の生理学的栄養補助剤または医薬:
−L-カルニチン 10%
−タウリン 2%
−ヒアルロン酸ナトリウム 0.2%
−ビタミンE 0.2%
−亜鉛 1.02 mg/L
−マンガン 0.051 mg/L
−ナトリウム 30 mg/L
−カリウム 9 mg/L。 - L-カルニチンの製薬的に許容される塩が以下を含む群から選択される、請求項1の生理学的栄養補助剤または医薬:塩化物、臭化物、オロト酸塩、アスパラギン酸塩、酸アスパラギン酸塩、酸クエン酸塩、クエン酸マグネシウム塩、リン酸塩、酸リン酸塩、フマル酸塩および酸フマル酸塩、フマル酸マグネシウム塩、乳酸塩、マレイン酸塩および酸マレイン酸塩、シュウ酸塩、酸シュウ酸塩、パモ酸塩、酸パモ酸塩、硫酸塩、酸硫酸塩、グルコースリン酸塩、酒石酸塩および酸酒石酸塩、グリセロリン酸塩、ムチン酸塩、酒石酸マグネシウム塩、2-アミノ-エタンスルホン酸塩、2-アミノ-エタンスルホン酸マグネシウム塩、メタンスルホン酸塩、コリン酒石酸塩、トリクロロ酢酸塩、およびトリフルオロ酢酸塩。
- 抗酸化剤;ボリジオイル;上皮形成および抗血管形成剤;シチコリン;増湿剤;無機成分;細胞モル浸透圧濃度の制御因子;抗生物質;抗ウイルス剤;抗真菌剤;および/または、アセチル、プロピオニル、バレリル、イソバレリル、ブチリルおよびイソブチリルL-カルニチンからなる群から選択される1以上のアルカノイルL-カルニチンまたはそれらの製薬的に許容される塩をさらに含む、請求項1または2の生理学的栄養補助剤または医薬。
- 抗酸化剤が、ビタミンCまたはビタミンAである、請求項4の生理学的栄養補助剤または医薬。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06125770 | 2006-12-11 | ||
EP06125770.5 | 2006-12-11 | ||
PCT/EP2007/062610 WO2008071524A1 (en) | 2006-12-11 | 2007-11-21 | Use of l-carnitine for the preparation of a medicament in the form of eye-drops for treating corneal diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010512363A JP2010512363A (ja) | 2010-04-22 |
JP5384362B2 true JP5384362B2 (ja) | 2014-01-08 |
Family
ID=37603705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009540692A Expired - Fee Related JP5384362B2 (ja) | 2006-12-11 | 2007-11-21 | 角膜疾患を処置するための点眼剤の形態の医薬の調製におけるl−カルニチンの使用 |
Country Status (13)
Country | Link |
---|---|
US (1) | US8158679B2 (ja) |
EP (1) | EP2091529A1 (ja) |
JP (1) | JP5384362B2 (ja) |
KR (1) | KR101447601B1 (ja) |
CN (1) | CN101534812B (ja) |
AU (1) | AU2007332680B2 (ja) |
BR (1) | BRPI0720089A2 (ja) |
CA (1) | CA2667069C (ja) |
EA (1) | EA017752B1 (ja) |
HK (1) | HK1135019A1 (ja) |
MX (1) | MX2009005503A (ja) |
SG (1) | SG176481A1 (ja) |
WO (1) | WO2008071524A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SG176525A1 (en) * | 2006-12-22 | 2011-12-29 | Sigma Tau Ind Farmaceuti | Gel useful for the delivery of ophthalmic drugs |
TW201322982A (zh) * | 2011-11-01 | 2013-06-16 | Otsuka Pharma Co Ltd | 用於治療前眼疾病之藥劑,該藥劑包含瑞巴派特及眼淚保持劑 |
EP2783695A1 (en) * | 2013-03-28 | 2014-10-01 | SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A. | Physiological supplement or medicament for ophthalmic use containing L-carnitine or alkanoyl L-carnitines in combination with eledoisin |
FR3019465B1 (fr) * | 2014-04-02 | 2017-06-23 | Horus Pharma | Composition hyperosmolaire d'acide hyaluronique et son utilisation pour le traitement de l'oedeme corneen |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08133968A (ja) * | 1994-09-14 | 1996-05-28 | Taisho Pharmaceut Co Ltd | 角膜障害修復用点眼液 |
US6585987B1 (en) * | 1998-11-13 | 2003-07-01 | Continental Projects Limited | Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions |
RU2165749C1 (ru) * | 2000-07-06 | 2001-04-27 | Общество с ограниченной ответственностью "Научно-экспериментальное производство Микрохирургия глаза" | Способ восстановления эндотелия роговицы |
US7465463B2 (en) * | 2002-09-04 | 2008-12-16 | Polyheal, Ltd. | Compositions comprising microspheres with anti-inflammatory properties for healing of ocular tissues |
US7820639B2 (en) * | 2004-10-01 | 2010-10-26 | Lindstrom Richard L | Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same |
US8569367B2 (en) * | 2004-11-16 | 2013-10-29 | Allergan, Inc. | Ophthalmic compositions and methods for treating eyes |
BRPI0612596A2 (pt) * | 2005-07-01 | 2010-11-23 | Sigma Tau Ind Farmaceuti | uso de l-carnitina ou alcanoil-l-carnitinas para a preparação de um suplemento ou medicamento fisiológico para uso oftálmico na forma de gotas oftálmicas |
-
2007
- 2007-11-21 CN CN2007800420044A patent/CN101534812B/zh not_active Expired - Fee Related
- 2007-11-21 AU AU2007332680A patent/AU2007332680B2/en not_active Ceased
- 2007-11-21 EP EP07822768A patent/EP2091529A1/en not_active Withdrawn
- 2007-11-21 JP JP2009540692A patent/JP5384362B2/ja not_active Expired - Fee Related
- 2007-11-21 KR KR1020097010677A patent/KR101447601B1/ko not_active IP Right Cessation
- 2007-11-21 BR BRPI0720089-7A2A patent/BRPI0720089A2/pt not_active IP Right Cessation
- 2007-11-21 EA EA200970562A patent/EA017752B1/ru not_active IP Right Cessation
- 2007-11-21 SG SG2011083714A patent/SG176481A1/en unknown
- 2007-11-21 WO PCT/EP2007/062610 patent/WO2008071524A1/en active Application Filing
- 2007-11-21 MX MX2009005503A patent/MX2009005503A/es active IP Right Grant
- 2007-11-21 US US12/515,142 patent/US8158679B2/en not_active Expired - Fee Related
- 2007-11-21 CA CA2667069A patent/CA2667069C/en not_active Expired - Fee Related
-
2009
- 2009-12-24 HK HK09112163.7A patent/HK1135019A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US8158679B2 (en) | 2012-04-17 |
BRPI0720089A2 (pt) | 2013-12-24 |
CN101534812A (zh) | 2009-09-16 |
KR101447601B1 (ko) | 2014-10-07 |
CA2667069C (en) | 2015-05-26 |
JP2010512363A (ja) | 2010-04-22 |
CN101534812B (zh) | 2012-09-05 |
MX2009005503A (es) | 2009-06-04 |
WO2008071524A1 (en) | 2008-06-19 |
EA017752B1 (ru) | 2013-02-28 |
AU2007332680A1 (en) | 2008-06-19 |
EP2091529A1 (en) | 2009-08-26 |
SG176481A1 (en) | 2011-12-29 |
HK1135019A1 (en) | 2010-05-28 |
KR20090087453A (ko) | 2009-08-17 |
CA2667069A1 (en) | 2008-06-19 |
US20100068300A1 (en) | 2010-03-18 |
EA200970562A1 (ru) | 2009-10-30 |
AU2007332680B2 (en) | 2013-02-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI404526B (zh) | L-肉毒鹼或烷醯基l-肉毒鹼供製造滴劑形式之眼用生理補充劑或藥劑上之用途 | |
CN102753163B (zh) | 用于预防和/或治疗由紫外线辐射导致的眼病的包含与羟基犬尿氨酸O-β-DL-葡萄糖苷相组合的L-肉碱作为活性成分的组合物 | |
JP5384362B2 (ja) | 角膜疾患を処置するための点眼剤の形態の医薬の調製におけるl−カルニチンの使用 | |
WO2008071528A1 (en) | Use of l-carnitine or of alkanoyl l-carnitines for the preparation of a physiological supplement or medicament for ophthalmic use in the form of eye drops | |
US20110268817A1 (en) | Compounds useful for the prevention or treatment of accomodative asthenopia | |
EP2783695A1 (en) | Physiological supplement or medicament for ophthalmic use containing L-carnitine or alkanoyl L-carnitines in combination with eledoisin | |
US20240122900A1 (en) | Use of l-ergothioneine to ameliorate and prevent age-related vitreous degeneration | |
RU2367387C1 (ru) | Способ лечения начальной катаракты | |
WO2020152527A1 (en) | Ophthalmic pharmaceutical compositions based on vitamins, amino acids and minerals for treating immature cataract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101110 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20121106 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130205 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130402 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130801 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20130812 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20130903 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20131002 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
LAPS | Cancellation because of no payment of annual fees |